0001209191-19-062314.txt : 20191231 0001209191-19-062314.hdr.sgml : 20191231 20191231171547 ACCESSION NUMBER: 0001209191-19-062314 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20191231 DATE AS OF CHANGE: 20191231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BioLexis Pte Ltd. CENTRAL INDEX KEY: 0001716335 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 191320067 BUSINESS ADDRESS: STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE CITY: SINGAPORE STATE: U0 ZIP: 068877 BUSINESS PHONE: 962 6 582 7999 MAIL ADDRESS: STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE CITY: SINGAPORE STATE: U0 ZIP: 068877 FORMER NAME: FORMER CONFORMED NAME: GMS Tenshi Holdings Pte. Ltd DATE OF NAME CHANGE: 20170906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pillai Arun Kumar CENTRAL INDEX KEY: 0001717437 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 191320068 MAIL ADDRESS: STREET 1: #30, "GALAXY," 1ST MAIN STREET 2: J.P. NAGAR 3RD PHASE CITY: BANGALORE STATE: K7 ZIP: 560078 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sukhtian Ghiath M. CENTRAL INDEX KEY: 0001717441 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 191320069 MAIL ADDRESS: STREET 1: 7TH CIRCLE, ZAHRAN ST. STREET 2: ZAHRAN PLAZA BUILDING, 4TH FLOOR CITY: AMMAN STATE: M2 ZIP: 11844 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-31 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001716335 BioLexis Pte Ltd. 36 ROBINSON ROAD #13-01 CITY HOUSE SINGAPORE U0 068877 SINGAPORE 1 0 1 0 0001717437 Pillai Arun Kumar #30, 1ST MAIN J.P. NAGAR 3RD PHASE BANGALORE K7 560078 INDIA 1 0 1 0 0001717441 Sukhtian Ghiath M. 7TH CIRCLE, ZAHRAN STREET ZAHRAN PLAZA BLDG, 4TH FLOOR AMMAN M2 11844 JORDAN 1 0 1 0 Series A-1 Convertible Preferred Stock 2019-12-31 4 J 0 1661 0.00 A Common Stock 31389 68112 D Each share of the Series A-1 Convertible Preferred Stock (the "Series A-1") is convertible into shares of the Issuer's common stock, par value $0.01 per share ("Shares") at any time at the election of the holder. The Series A-1 has no expiration date. Represents shares of Series A-1 received by BioLexis Pte Ltd. ("BioLexis") as a payment-in-kind dividend on previously acquired Series A-1. These securities are held of record by BioLexis. Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma. By virtue of the relationships described above in Footnote 3, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Biolexis Pte Ltd., By: Faisal G. Sukhtian, Director 2019-12-31 /s/ Arun Kumar Pillai 2019-12-31 /s/ Ghiath M. Sukhtian 2019-12-31